Kardigan IPO: 8 Things to Know Before KARD’s $1.4B Nasdaq Debut

Kardigan has no product revenue, yet its IPO targets a valuation near $1.4 billion. The case rests on three cardiovascular drugs, Danicamtiv, Ataciguat, and Tonlamarsen, with decisive data expected in 2027. 

With 23.3 million shares offered at $14 to $16, Kardigan's IPO Nasdaq debut asks public markets to price the pipeline before the evidence arrives.

Kardigan IPO Key Takeaways

• Kardigan plans to offer 23.3 million shares at $14 to $16 per share, with KARD expected to list on Nasdaq on June 18, 2026.

• The IPO would raise about $350 million at the midpoint, placing Kardigan among the larger clinical-stage biotech listings of 2026.

• The valuation target is in the $1.3 billion to $1.4 billion range, despite $0 in product revenue and a net loss of roughly $230 million for the 12 months ended March 31, 2026.

• The IPO case rests on three cardiovascular programs: Danicamtiv, Ataciguat, and Tonlamarsen.

• The deciding evidence arrives in 2027, with Danicamtiv, Ataciguat, and Tonlamarsen each facing data points that could either support or weaken the IPO valuation.

Kardigan IPO Details Overview

The key figure is product revenue: $0. Kardigan is asking public markets to price future clinical proof rather than current sales.

1. What Does Kardigan Do?

Kardigan is a clinical-stage biotechnology company developing cardiovascular therapies for diseases where treatment options remain limited or poorly targeted. Its IPO case rests on three programs: Danicamtiv for genetic dilated cardiomyopathy, Ataciguat for moderate calcific aortic valve stenosis, and Tonlamarsen for acute severe hypertension after hospitalization.

KARD is not coming public with approved drugs or product revenue. It is coming public with three late-stage cardiovascular assets and a 2027 data calendar that will decide whether the science can support a valuation above $1 billion.

2. Why Kardigan’s $350M IPO Is Larger Than a Simple Funding Round

Kardigan’s proposed $350 million raise is large enough to make the IPO a market test, not just a company financing. Kardigan’s deal asks for more than runway; it asks for confidence in late-stage cardiovascular data that will not arrive until 2027.

At the $15 midpoint, Kardigan expects estimated net proceeds of $320.3 million, or about $369.1 million if underwriters fully exercise their option to buy additional shares. That capital is meant to carry Danicamtiv, Ataciguat, and Tonlamarsen toward major clinical milestones, not toward near-term product sales.

The expected June 18, 2026, debut arrives in a selective biotech IPO window where size does not guarantee demand. Final pricing against the $14 to $16 range will show whether public markets are willing to advance capital before the decisive data arrive.

3. The $1.4B Valuation Depends on 2027 Data, Not Current Sales

Kardigan’s valuation has no revenue anchor. The company reported $0 product revenue and a net loss of roughly $230 million for the 12 months ended March 31, 2026, leaving the IPO case tied to clinical milestones rather than operating performance.

Cash gives Kardigan room to reach those milestones. The company had $287.1 million in cash, cash equivalents, and short-term investments as of March 31, 2026, before the IPO proceeds. It also recorded a $56.1 million net loss in the first quarter and an accumulated deficit of $337.2 million.

The balance sheet improves after the IPO, but the valuation still depends on evidence from Danicamtiv, Ataciguat, and Tonlamarsen. Cash can carry the programs into 2027; it cannot prove the drugs work.

4. Kardigan’s Pipeline Splits the IPO Risk Three Ways

Kardigan’s pipeline can be read through three 2027 signals: the lead validation test, the market-expansion test, and the risk-confirmation test.

Danicamtiv carries the highest weight because it is the clearest test of whether Kardigan’s precision-cardiovascular strategy can justify a valuation above $1 billion.

5. Danicamtiv Carries the First Major 2027 Test

Danicamtiv is an oral cardiac myosin activator for genetic dilated cardiomyopathy, including disease associated with MYH7 and TTN variants. The clinical gap is clear: approved treatments manage heart failure progression, but none directly target the genetic drivers that Kardigan is pursuing.

KINSHIP-DCM is the first major test. Kardigan expects topline data from the Phase 2b portion of the trial in the first half of 2027.

A positive result would do more than support one drug. It would validate the central logic behind KARD’s valuation: precision cardiovascular therapy can move from genetic targeting to measurable clinical benefit.

6. Ataciguat Gives Kardigan a Second Cardiovascular Bet

Ataciguat targets moderate calcific aortic valve stenosis, a disease stage at which patients are often monitored until progression becomes severe enough to warrant valve intervention. The appeal is simple: a drug that slows calcification before surgery enters the conversation would create a rare disease-modifying angle in structural heart disease.

The evidence base remains small. In a Phase 2 trial of 23 patients with moderate CAVS, Kardigan reported slower progression of aortic valve calcification compared with placebo, with additional signals in valve compliance and cardiac function.

Scale is the next test. Kardigan expects 24-week data in H1 2027 and 48-week data in H2 2027 from KATALYST-AV. For Ataciguat to matter to the IPO case, early calcification signals must translate into endpoints that look durable in a larger study.

7. Tonlamarsen Adds Breadth, but Its Efficacy Case Is Less Clean

Tonlamarsen is the least settled signal in Kardigan’s late-stage pipeline. The drug is a once-monthly antisense oligonucleotide designed to reduce hepatic angiotensinogen, an upstream driver in the blood-pressure pathway.

The biomarker data were strong. Patients receiving five monthly doses achieved a 67% mean reduction in angiotensinogen, compared with 23% in the single-dose group. The harder clinical endpoint was weaker: Kardigan reported no significant difference in in-office systolic blood pressure between groups at Week 20, with p=0.97 on that co-primary endpoint.

The unresolved point is clinical translation. Tonlamarsen showed biological activity, but Week 20 office blood pressure did not separate between groups.

Kardigan has moved Tonlamarsen toward acute severe hypertension after hospitalization, with Phase 2b topline data expected in H1 2027. The next readout needs to close the gap between biological activity and clinical effect.

8. The IPO Proceeds Extend Runway, but Funding Risk Remains

Kardigan’s IPO proceeds are built around the 2027 data calendar. The company plans to allocate $80 million to $90 million each to Danicamtiv and Ataciguat, plus $40 million to $50 million to Tonlamarsen, taking all three programs through key Phase 2b milestones and toward the start of Phase 3.

Another $50 million to $60 million is earmarked for broader research and development, with the remainder for working capital and general corporate purposes. Combined with existing cash and short-term investments, the IPO is expected to fund operations into 2028.

The funding caveat is explicit in the filing. Management and the independent auditor raised substantial doubt about Kardigan’s ability to continue as a going concern before the offering because existing resources were not expected to fund operations for at least 12 months after the financial statement issuance date.

The IPO narrows that funding gap, but it does not eliminate the next capital question. Kardigan still says additional funds will be needed to fully execute the planned use of proceeds.

Frequently Asked Questions

When is the Kardigan IPO date?

Kardigan is listed on the IPO calendar for June 18, 2026, with plans to trade on Nasdaq under the ticker KARD. The date can still shift if final pricing or listing conditions change.

What is the Kardigan IPO price range?

Kardigan plans to offer 23.3 million shares at $14 to $16 per share. At the $15 midpoint, the IPO would raise about $350 million in gross proceeds.

What does Kardigan do?

Kardigan develops cardiovascular therapies. The IPO is built around Danicamtiv, Ataciguat, and Tonlamarsen, three clinical programs targeting genetic dilated cardiomyopathy, moderate calcific aortic valve stenosis, and acute severe hypertension after hospitalization.

Is Kardigan profitable?

No. Kardigan has $0 product revenue, a $56.1 million net loss for Q1 2026, and an accumulated deficit of $337.2 million as of March 31, 2026.

What could make the Kardigan IPO disappoint?

The IPO can disappoint if final pricing weakens, trial timelines slip, or 2027 data fail to support the valuation. Tonlamarsen already shows the risk: strong biological activity did not yet translate into clean office blood-pressure separation.

The Next Signal Is the Final IPO Price

Listing day will test demand, not the science. The first signal is where KARD prices against the $14 to $16 range, because that will show how much confidence public markets are willing to advance before the 2027 readouts.

The clinical verdict comes later. Danicamtiv, Ataciguat, and Tonlamarsen still need to prove that their late-stage cardiovascular promise can translate into measurable treatment value.

KARD’s first trade will measure appetite; its real test begins when the 2027 data arrive.